Hungry Bone Syndrome Associated with Transient Hypoparathyroidism

Case Report


Abstract

We report on an infant who presented at 50 days old of age with hypocalcemic seizure, who proved to have transient hypoparathyroidism, biochemically. During the course of his therapy, he developed severe hungry bone syndrome. Hungry bone syndrome and transient hypoparathyroidism is highlighted.

Keywords: Hypoparathyroidism; Hungry Bone Syndrome; Infant; Transient.

Introduction

Hypoparathyroidism is a state of inadequate parathyroid hormone (PTH). It results from defective synthesis or secretion of PTH, end organ resistance, or inappropriate regulations. Hypoparathyroidism may be transient, genetically inherited or acquired. Transient usually occurs during neonatal period or secondary to medication. The ionized calcium concentration, in extra cellular fluid (ECF), falls below reference range, where at birth parathyroid gland have a limited ability to respond to decrease in serum calcium [1-4]. The term "hungry bone syndrome" HBS has been coined to the profound, serum calcium of less than 2.1 mmol and prolonged hypocalcemia. The severe hypocalcemia is believed to be due to deposition of calcium in bones [5, 6].

We present an infant with transient hypoparathyroidism who developed severe hungry bone syndrome. Such an association is highlighted.

Case Presentation

A full term, 50 day-old Saudi male boy, presented to the emergency department with afebrile tonic-clonic seizure lasting for several minutes and aborted by rectal diazepam. Pregnancy and neonatal history was unremarkable, in particular the mother was not on any medication. No family history of seizure disorder. He was appropriate for age and there was no dysmorphic features. Initial serum calcium (Ca) was low at 1.4 mmol (normal 2.2 - 2.5 ), inorganic phosphate (P) 3.25 mmol (normal 1.4 -2.1), and alkaline phosphatase activity (ALP) 150 U/L (normal <600), serum magnesium (Mg) 1.4 mmol/L ( normal 0.8 - 1.6 ), parathyroid hormone (PTH) was 0.127 pmol/L ( normal 1.6 - 6.9), and 25 hydroxy vitamin D 75 nmol/ L (normal > 50). Normal chest x ray, and normal echocardiogram. The child was not septic. Mother's bone profile, 25 hydroxy vitamin D and PTH concentration were normal.

The patient was initially managed with intravenous calcium infusion, then later with oral calcium (50mg/kg/day) in four divided doses and calcitriol (1,25 dihydroxycholecalciferol ). Three week later re-admitted again with afebrile seizure, serum calcium was 1.2 mmol/L.(normal 2.2 - 2.5). He require high dose of calcium (200mg/kg/day), in addition to calcitriol. No further seizure, and was discharged after one week of hospitalization on calcium and calcitriol, with serum calcium of 2.3 mmol/L, subsequently he was followed in the endocrine clinic, and within three months his medication were gradually withdrawn. He continued to be well

*Corresponding Author:
Nasir A.M. Al-Jurayyan MD,
Professor and Senior Consultant Pediatric Endocrinologist, Division of Endocrinology, Department of Pediatrics, College of Medicine, King Saud University, Riyadh Saudi Arabia.
Tel: 0505400592
E-mail: njurayyan@gmail.com

Received: May 19, 2017
Accepted: July 06, 2017
Published: July 07, 2017


Copyright: Al-Jurayyan NA* 2017, This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
off therapy with serum calcium ranging between 2.2 - 2.4 mmol/L, and serum concentration of PTH 3.2 pmol/L (normal 1.6 - 6.9). At time of reporting the case, he is currently 5 years of age with normal bone profile and PTH serum concentration. He is neurodevelopmentally appropriate for age.

Discussion

Hypoparathyroidism is a state of inadequate parathyroid hormone (PTH), which results from defect in synthesis, secretion, unresponsive end organ, or inappropriate regulation of the hormone. It could be transient usually in the neonatal period or associated with use of some medications as in amphotericin B, which can lead to hypomagnesia which is an important cofactor for parathyroid hormone. The diagnosis of transient hypoparathyroidism, in our patient, was established on basis of low PTH and calcium, with high phosphate and normal alkaline phosphatase, which returned to normal after three months of therapy. The infant did not receive any medications such as amphotericin B nor had hypomagnesia. The mother did not have hyperparathyroidism and she never consumed alcohol, or were on any medications containing calcium. Maternal hyperparathyroidism causing hypercalcemia during pregnancy and can suppress fetal and neonatal parathyroid hormone (PTH) secretion. As a consequence, transient neonatal hypoparathyroidism can occur in an infant born to a mother with untreated hyperparathyroidism [1-4, 7-11]. Hungry bone syndrome was first reported in 1948. Extensive mineralization of the bone, reflecting deposition of calcium and phosphate within the bone parenchyma [12]. Our patient required a very high dose of oral calcium with no clinical evidence of malabsorption. Hungry bone syndrome should be considered in differential diagnosis of hypocalcemia. Close monitoring of calcium with aggressive calcium replacement at the earliest is essential to prevent neuromuscular complications and seizures. Earliest detection of the risk factors for HBS and treatment with calcitriol/biphosphonate may reduce potentially life threatening hypocalcemia in similar patients.

Hungry bone syndrome is a clinical entity which is accompanying hypocalcemia and hypomagnesemia resulting from an increase in bone formation. It is related to a pathological scenario which causes an imbalance between osteoclast mediated bone resorption, and osteoblast mediated bone resorption, favoring the latter due to plasmatic calcium level reduction [5, 6, 12, 13].

Conclusion

Hungry bone syndrome is a well known entity associated with treatment of hypocalcemia. Continuous and frequent serum calcium monitoring is mandatory to avoid the two extreme complications, hypo and hypercalcemia.

Acknowledgement

The authors would like to thank Ms. Hadeel N. Al-jurayyan for her help in preparing this manuscript.

References